Management of Ventricular Tachycardia in Myocardial Infarction

Introduction to Treatment Guidelines

• The American College of Cardiology/American Heart Association (ACC/AHA) recommends amiodarone as the preferred antiarrhythmic agent for sustained monomorphic ventricular tachycardia (VT) in the context of myocardial infarction (MI) 1

Treatment Algorithm for Ventricular Tachycardia

• For hemodynamically unstable VT, immediate synchronized electrical cardioversion with an initial monophasic shock of 100J is recommended, with increasing energies if the initial shock is unsuccessful 1
• For hemodynamically stable VT, intravenous amiodarone is recommended, with a dose of 150 mg over 10 minutes, followed by an infusion of 1.0 mg/min for 6 hours, then maintenance at 0.5 mg/min 1, 2
• An alternative to amiodarone for hemodynamically stable VT is procainamide, with a loading infusion of 20-30 mg/min up to 12-17 mg/kg, followed by a 1-4 mg/min infusion 2

Role of Beta-Blockers in Cardiac Care

• Beta-blockers are primarily indicated for rate control in atrial fibrillation/flutter, certain forms of polymorphic VT associated with acute ischemia, and reducing myocardial oxygen demand in ongoing ischemia 3, 4

Risks of Using Esmolol for VT in MI Patients

• Using esmolol for VT in MI patients can cause or worsen hypotension, precipitate or worsen heart failure, mask signs of cardiogenic shock, and cause bradycardia, especially in inferior MI 5, 6

Special Considerations for Inferior Wall MI

• In patients with inferior wall MI, beta-blockers must be used with extreme caution due to the increased risk of bradycardia and heart block 7
• The COMMIT study showed that early aggressive beta blockade can increase the risk of cardiogenic shock in hemodynamically unstable patients 5